Clinical Trials

140 enrolled

Solid Tumor, Adult

NCT06270706 2024-06-12

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

BreastDermatologicGastrointestinalGenitourinaryGynecologic

77 enrolled

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02557321 2023-11-21

PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma

50 enrolled

Dermatologic

Melanoma

NCT04294576 2023-11-09

FIH

92 enrolled

Locally Advanced/Metastatic Solid Tumors

NCT05986331 2023-09-21

Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced Melanoma

Phase 3 Unknown

366 enrolled

Dermatologic

Melanoma

NCT05296772 2023-09-06

Phase 1 First-in-human Study of JS014

60 enrolled

Lymphoid

Lymphoma, Neoplasms, Neoplasms, Experimental

NCT05739006 2023-08-02

Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies

131 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT05708950 2023-07-13

A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

314 enrolled

Breast Neoplasms, Carcinoma, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms

NCT05127590 2023-07-03

RBN-2397 in Combination With Pembrolizumab in Patients With SCCL

50 enrolled

Thoracic

Advanced Squamous Non-Small Cell Lung Carcinoma

NCT03567720 2023-06-01

Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC

65 enrolled

Breast

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT03132675 2023-03-27

Keynote-695

143 enrolled

Dermatologic

Melanoma

NCT05647954 2022-12-13

A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver

Phase 3 Unknown

350 enrolled

DermatologicEndocrineNET

Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms

NCT05042375 2022-11-17

A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer

Phase 3 Unknown

450 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02675946 2022-01-26

CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)

72 enrolled

Gastrointestinal

Gastrointestinal Neoplasms

NCT05053880 2021-11-19

A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme

48 enrolled

CNS

Glioblastoma, Neoplasms

NCT04859777 2021-09-16

A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors

70 enrolled

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT04024800 2021-06-02

NSABP FB-14

29 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04866485 2021-04-29

A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 Antibody

66 enrolled

Solid Tumor

NCT04860076 2021-04-26

Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors

Unknown

400 enrolled

DermatologicThoracic

Lung Neoplasms, Melanoma

NCT03771820 2021-03-17

Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen

136 enrolled

SCCHN

NCT04750083 2021-02-11

HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Phase 2/3 Unknown

700 enrolled

Thoracic

Nonsquamous Non-small Cell Lung Cancer

NCT04699643 2021-01-07

FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors

80 enrolled

Advanced Solid Tumors

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.